Market Cap 639.14M
Revenue (ttm) 311.71M
Net Income (ttm) 163.06M
EPS (ttm) N/A
PE Ratio 4.33
Forward PE 15.24
Profit Margin 52.31%
Debt to Equity Ratio 0.00
Volume 1,496,700
Avg Vol 1,352,854
Day's Range N/A - N/A
Shares Out 77.94M
Stochastic %K 59%
Beta 1.50
Analysts Strong Sell
Price Target $14.14

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 517 9500
Address:
389 Interpace Pkwy, Suite 450, Parsippany, United States
Noname2022
Noname2022 Aug. 24 at 3:04 PM
0 · Reply
wolfofwestloop
wolfofwestloop Aug. 24 at 1:53 PM
$CRMD unfortunately the street believes that Defencath margins moving forward will be relatively low. Until proven otherwise the share price will bounce between 7-9... They also feel that this undervalued with the uptick in Institutional owenership. It's hard to believe if the Defencath becomes SOC this isn't a $30-40 stock on Defencath alone unless they are giving it away.
0 · Reply
btdb
btdb Aug. 24 at 6:08 AM
$CRMD It really is amazing how low the expectations are for CRMD to utilize its cash position successfully. Current cash is around 250MM for a company with a market cap around 650MM , so the actual enterprise value is only about 400MM on 77 million shares outstanding, more or less. That’s a share price of $5.20 for the value of the company sans cash position. P/E is under 3. Something is just not right, and I don’t think it’s my back of the envelope computation. GLTA. Two more quarters of aimlessly wandering financially until guidance is believable.
2 · Reply
Noname2022
Noname2022 Aug. 24 at 1:11 AM
$CRMD Looking forward to seeing whether CorMedix and DaVita submit comments nothing from either that I could find yet, with the deadline tomorrow.
0 · Reply
Noname2022
Noname2022 Aug. 24 at 1:08 AM
$CRMD One thing I noticed in the newer NUTRI-GUARD trial-design poster: randomization appears to have shifted from 2:1 to 1:1. If that’s the current design, more patients in the higher-event control arm should help the trial reach its event-driven interim faster.
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 23 at 8:55 PM
$CRMD 📊 USAEquityResearch ▼ 8.20 (-0.36%) Trend: Bullish 📈 RSI (14): 58.6 — neutral territory MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 8.52 | Support: 7.10 20-MA: 7.65 | 50-MA: 8.09 💼 Fundamentals Mkt Cap: $639.14M P/E (TTM): 3.8 | Fwd P/E: 23.4 FCF: $178.14M (2.29/sh) Total Debt: $147.46M D/E: 32.0 📉 Options (exp 2026-09-18) ATM IV: 53.3% | Skew: +0.0% (balanced) P/C Ratio: 0.6 🐂 Bullish lean Max Pain: 9.00 Call wall: 9.00 | Put wall: 8.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/CRMD
0 · Reply
wolfofwestloop
wolfofwestloop Aug. 23 at 3:12 PM
$CRMD Isn't it wild how long these regulatory filings take. Rezzayo study has been complete for 4 months and still no official filing. I'm not blaming the CRMD team for that but what a joke our government is.
1 · Reply
Noname2022
Noname2022 Aug. 23 at 3:48 AM
$CRMD Poster on TPN study design https://nhia.org/wp-content/uploads/2026/07/3359507.pdf
1 · Reply
Merlintrader
Merlintrader Aug. 22 at 6:29 PM
$CRMD Second-quarter revenue was 101.9 million dollars, net income 26.0 million and adjusted EBITDA 58.7 million. Full-year revenue guidance was maintained and adjusted EBITDA guidance raised, while DefenCath moved into the lower post-TDAPA reimbursement regime on July 1. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/cormedix-therapeutics-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-22ago2026
2 · Reply
wolfofwestloop
wolfofwestloop Aug. 22 at 6:07 PM
$CRMD frustrating how the institutions can accumulate so much while not moving the price...
0 · Reply
Latest News on CRMD
CorMedix reports Q2 EPS 29c vs. 28c last year

2026-08-17T07:58:32.000Z - 7 days ago

CorMedix reports Q2 EPS 29c vs. 28c last year


CorMedix Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 11 days ago

CorMedix Earnings Call Transcript: Q2 2026


CorMedix Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 11 days ago

CorMedix Earnings release: Q2 2026


CorMedix Quarterly report: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 11 days ago

CorMedix Quarterly report: Q2 2026


CorMedix price target lowered to $13 from $14 at RBC Capital

2026-07-07T11:30:10.000Z - 6 weeks ago

CorMedix price target lowered to $13 from $14 at RBC Capital


CorMedix Transcript: AGM 2026

Jun 23, 2026, 9:00 AM EDT - 2 months ago

CorMedix Transcript: AGM 2026


CorMedix Slides: Corporate presentation

May 22, 2026, 7:00 AM EDT - 3 months ago

CorMedix Slides: Corporate presentation


CorMedix Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 3 months ago

CorMedix Earnings Call Transcript: Q1 2026


CorMedix Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 3 months ago

CorMedix Earnings release: Q1 2026


CorMedix Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 3 months ago

CorMedix Quarterly report: Q1 2026


CorMedix reports Q1 EPS 43c, consensus 33c

2026-05-14T11:53:51.000Z - 3 months ago

CorMedix reports Q1 EPS 43c, consensus 33c


CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

CorMedix Proxy statement: Proxy filing


CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

CorMedix Proxy statement: Proxy filing


CorMedix price target raised to $14 from $13 at RBC Capital

2026-04-28T11:56:23.000Z - 4 months ago

CorMedix price target raised to $14 from $13 at RBC Capital


CorMedix announces ReSPECT clinical trial met primary endpoint

2026-04-27T12:05:37.000Z - 4 months ago

CorMedix announces ReSPECT clinical trial met primary endpoint


CorMedix Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

CorMedix Proxy statement: Proxy filing


CorMedix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:35 AM EDT - 5 months ago

CorMedix Transcript: The Citizens Life Sciences Conference 2026


CorMedix Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 5 months ago

CorMedix Transcript: Leerink Global Healthcare Conference 2026


CorMedix Slides: Corporate presentation

Mar 7, 2026, 6:00 AM EST - 6 months ago

CorMedix Slides: Corporate presentation


CorMedix price target lowered to $13 from $15 at Leerink

2026-03-06T17:05:52.000Z - 6 months ago

CorMedix price target lowered to $13 from $15 at Leerink


CorMedix Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

CorMedix Earnings Call Transcript: Q4 2025


CorMedix Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

CorMedix Annual report: Q4 2025


CorMedix Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 6 months ago

CorMedix Earnings release: Q4 2025


CorMedix reports Q4 EPS 16c vs 20c last year

2026-03-05T12:36:24.000Z - 6 months ago

CorMedix reports Q4 EPS 16c vs 20c last year


CorMedix to Participate in Upcoming Investor Conferences

Feb 12, 2026, 8:30 AM EST - 6 months ago

CorMedix to Participate in Upcoming Investor Conferences


CorMedix Transcript: Investor Day 2026

Feb 10, 2026, 1:00 PM EST - 6 months ago

CorMedix Transcript: Investor Day 2026


CorMedix Slides: FY 2026

Feb 10, 2026, 1:00 PM EST - 6 months ago

CorMedix Slides: FY 2026


CorMedix Therapeutics Announces Share Repurchase Program

Feb 2, 2026, 8:30 AM EST - 7 months ago

CorMedix Therapeutics Announces Share Repurchase Program


CorMedix price target lowered to $13 from $22 at RBC Capital

2026-01-21T11:35:46.000Z - 7 months ago

CorMedix price target lowered to $13 from $22 at RBC Capital


CorMedix Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 8 months ago

CorMedix Slides: Corporate presentation


CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:05 AM EST - 8 months ago

CorMedix Therapeutics Announces Leadership and Board Updates


CorMedix Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

CorMedix Earnings Call Transcript: Q3 2025


CorMedix Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

CorMedix Quarterly report: Q3 2025


CorMedix Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

CorMedix Earnings release: Q3 2025


CorMedix Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 10 months ago

CorMedix Proxy statement: Proxy Filing


CorMedix Proxy statement: Proxy Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

CorMedix Proxy statement: Proxy Filing


CorMedix Registration statement: Registration Filing

Sep 30, 2025, 8:00 AM EDT - 11 months ago

CorMedix Registration statement: Registration Filing


CorMedix Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing


CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 10:49 AM EDT - 1 year ago

CorMedix to Buy Melinta Therapeutics for $300 Million


CorMedix Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q2 2025


CorMedix Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

CorMedix Earnings release: Q2 2025


CorMedix inc. Announces Customer Implementation

Jun 23, 2025, 7:30 AM EDT - 1 year ago

CorMedix inc. Announces Customer Implementation


CorMedix Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q1 2025


CorMedix Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q1 2025


CorMedix Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings release: Q1 2025


CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing


CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing


Noname2022
Noname2022 Aug. 24 at 3:04 PM
0 · Reply
wolfofwestloop
wolfofwestloop Aug. 24 at 1:53 PM
$CRMD unfortunately the street believes that Defencath margins moving forward will be relatively low. Until proven otherwise the share price will bounce between 7-9... They also feel that this undervalued with the uptick in Institutional owenership. It's hard to believe if the Defencath becomes SOC this isn't a $30-40 stock on Defencath alone unless they are giving it away.
0 · Reply
btdb
btdb Aug. 24 at 6:08 AM
$CRMD It really is amazing how low the expectations are for CRMD to utilize its cash position successfully. Current cash is around 250MM for a company with a market cap around 650MM , so the actual enterprise value is only about 400MM on 77 million shares outstanding, more or less. That’s a share price of $5.20 for the value of the company sans cash position. P/E is under 3. Something is just not right, and I don’t think it’s my back of the envelope computation. GLTA. Two more quarters of aimlessly wandering financially until guidance is believable.
2 · Reply
Noname2022
Noname2022 Aug. 24 at 1:11 AM
$CRMD Looking forward to seeing whether CorMedix and DaVita submit comments nothing from either that I could find yet, with the deadline tomorrow.
0 · Reply
Noname2022
Noname2022 Aug. 24 at 1:08 AM
$CRMD One thing I noticed in the newer NUTRI-GUARD trial-design poster: randomization appears to have shifted from 2:1 to 1:1. If that’s the current design, more patients in the higher-event control arm should help the trial reach its event-driven interim faster.
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 23 at 8:55 PM
$CRMD 📊 USAEquityResearch ▼ 8.20 (-0.36%) Trend: Bullish 📈 RSI (14): 58.6 — neutral territory MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 8.52 | Support: 7.10 20-MA: 7.65 | 50-MA: 8.09 💼 Fundamentals Mkt Cap: $639.14M P/E (TTM): 3.8 | Fwd P/E: 23.4 FCF: $178.14M (2.29/sh) Total Debt: $147.46M D/E: 32.0 📉 Options (exp 2026-09-18) ATM IV: 53.3% | Skew: +0.0% (balanced) P/C Ratio: 0.6 🐂 Bullish lean Max Pain: 9.00 Call wall: 9.00 | Put wall: 8.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/CRMD
0 · Reply
wolfofwestloop
wolfofwestloop Aug. 23 at 3:12 PM
$CRMD Isn't it wild how long these regulatory filings take. Rezzayo study has been complete for 4 months and still no official filing. I'm not blaming the CRMD team for that but what a joke our government is.
1 · Reply
Noname2022
Noname2022 Aug. 23 at 3:48 AM
$CRMD Poster on TPN study design https://nhia.org/wp-content/uploads/2026/07/3359507.pdf
1 · Reply
Merlintrader
Merlintrader Aug. 22 at 6:29 PM
$CRMD Second-quarter revenue was 101.9 million dollars, net income 26.0 million and adjusted EBITDA 58.7 million. Full-year revenue guidance was maintained and adjusted EBITDA guidance raised, while DefenCath moved into the lower post-TDAPA reimbursement regime on July 1. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/cormedix-therapeutics-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-22ago2026
2 · Reply
wolfofwestloop
wolfofwestloop Aug. 22 at 6:07 PM
$CRMD frustrating how the institutions can accumulate so much while not moving the price...
0 · Reply
Noname2022
Noname2022 Aug. 22 at 2:28 PM
Really appreciate Pesh Patel’s patient advocacy and persistence in helping expand access to DefenCath for dialysis patient $CRMD https://www.instagram.com/reel/DN0yNo3Yn-W/
0 · Reply
wolfofwestloop
wolfofwestloop Aug. 21 at 9:36 PM
$CRMD CRMD has all this cash sitting on the sidelines. They should take 10 -20M and do a special dividend payment to its shareholders.
3 · Reply
Spoonorama
Spoonorama Aug. 21 at 8:33 PM
$CRMD Usually there's candles of about 300-500k AH but today was huge. Over 1 million candle right after close.
3 · Reply
Derek22us
Derek22us Aug. 21 at 7:22 PM
$CRMD The lowest form of human life..........An ask price dropping dirtbag.
0 · Reply
CaliEmpress
CaliEmpress Aug. 21 at 7:14 PM
$CRMD I don’t blame you for selling for a profit, that’s smart but as for me, I am here for the journey.
1 · Reply
Derek22us
Derek22us Aug. 21 at 6:11 PM
$CRMD Fascinating and gag reflex triggering to watch the penny skimming flip flopping 700 and 1100 scavengers.
0 · Reply
Derek22us
Derek22us Aug. 21 at 5:42 PM
$CRMD Disgusting trading trash being led by the 700 and 1100 scamming sheisters.
0 · Reply
5dollaHayaCut
5dollaHayaCut Aug. 21 at 5:17 PM
$CRMD the davita news meant literally NOTHING to the market. NOTHING.
1 · Reply
5dollaHayaCut
5dollaHayaCut Aug. 21 at 5:17 PM
$CRMD i fking told yall he’s just a pumper lol
0 · Reply
hopedoesntGAF
hopedoesntGAF Aug. 21 at 5:15 PM
$CRMD I'm out this mornings before my endoscopy, at 8.38... Made 1327.00....on 4600 shares Call me a pumper.... wuteva.. Disappointed that it couldn't reclaim the 200 ma, 8.40 now, but I do have a buy stop order at 8.45 in case this drop is a headfake...doubt it. Longterm, I truly believe that stock is at least a double from the 7.10 low, and I will be looking for a retest of mid to low 7s. MMs are happy, today is options expiry, the 1600 8 buck puts are deader than 5 dolla haitcu^t's noodle. And those poor fackers that own the 2300 9 buck calls are also toast. Longs have a winner here, you just need to tune out the noise and hold, add mid to low 7s if possible and wait it out until the MA clusterfack is resolved. Probably early 2027. Not my style. People here saying MA isn't going to happen are FOS. History favors treatments that avoid a costly life saving process over a $280.00 buck alternative. The thing is time, they will avoid it like the plague for now.
1 · Reply
chauncyv
chauncyv Aug. 21 at 4:20 PM
$CRMD is a $15 call option for march 2027 smart lol. only .30
2 · Reply
Noname2022
Noname2022 Aug. 21 at 3:53 PM
Great perspective from one of our reps. In pharma, the work often happens long before the results become visible. Consistency, relationships, and repeated touches eventually move the needle. $CRMD
0 · Reply